This week we discuss some recent publications relevant to EM: ADRENAL, Idarucizumab and Time to Furosemide.
Episode 141.0 – Journal Update
Show Notes
Read More
Core EM: Idarucizumab for Reversal of Dabigitran
Core EM: Idarucizumab for Reversal of Dabigitran II
First10EM: Idarucizumab: Plenty of Optimism, Not Enough Science
EM Lit of Note: The Door-to-Lasix Quality Measure
EMS MED: When It’s More Complicated Than A Tweet: Door-To-Furosemide And EMS
REBEL EM: Door to Furosemide (D2F) in Acute CHF . . . Really?
emDocs.net: Furosemide in the Treatment of Acute Pulmonary Edema
Core EM: Door-to-Furosemide Time
References
Pollack et al. Idarucizumab for dabigitran reversal – full cohort analysis. NEJM 2017; 377(5): 431-41. PMID: 28693366
Matsue Y et al. Time-to-Furosemide Treatment and Mortality in Patients Hospitalized with Acute Heart Failure J Am Coll Cardiol 2017; 69(25): 3042-51. PMID: 28641794
